A large-sample multi-center random control trial of precise treatment of early cervical cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035569

Enrollment

Unknown

Registered

2020-08-13

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

control group:traditionaltreatment

Experimental group:precise treatment

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Newly treated cervical cancer patients aged 18-65 years; (2) Stage IA1(LVSI+) to IIA1 cerivical cancer(FIGO stage, 2018). (3) Preoperative imaging showed no lymph node metastasis. (4) The pathological types were squamous cell carcinoma, adenocarcinoma (common type) or squamous cell adenocarcinoma.

Exclusion criteria

Exclusion criteria: (1) Patients who have received neoadjuvant chemotherapy or radiotherapy; (2) a history of myocardial infarction or stroke, unstable angina pectoris, decompensated heart failure, or deep vein thrombosis; (3) liver insufficiency; (4) renal insufficiency; (5) A history of chronic pulmonary disease with limited respiratory dysfunction.

Design outcomes

Primary

Measure	Time frame
Recurrence-free survival;Overall survival;	—

Secondary

Measure	Time frame
intraoperative and postoperative complications;adverse reactions;Quality of life;pregnancy rate;	—

Countries

China

Contacts

Public ContactKeqin Hua

Obstetrics and Gynecology Hospital of Fudan University

huakeqin@126.com+86 15921515900

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026